SCHEMBL7529291

SCHEMBL7529291

CC(C)NC(C#N)C(NC(C)C)OP

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8729468 0.70 TDP1 (0.40)
SCHEMBL9341155 0.61
SCHEMBL297923 0.59
SCHEMBL27280425 0.59
SCHEMBL5823201 0.59
SCHEMBL25453160 0.59
SCHEMBL25709616 0.59
Acetonitrile SCHEMBL953246 0.58 TDP1 (0.61)
Acetonitrile SCHEMBL1526829 0.58 TDP1 (0.61)
SCHEMBL8442969 0.58 TDP1 (0.61)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0635023-B1 COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES ISIS PHARMACEUTICALS INC (US) 2002-02-06 EP disclosed
US-5719271-A HYBRIDS; GENETIC ENGINEERING ISIS PHARMACEUTICALS, INC. (US) 1998-02-17 US disclosed
US-5543507-A BONDING STRANDS OR ONE STRAND AT DIFFERENT SITES; RNA MIMICS FIXED IN SPATIAL CONFORMATION; NUCLEASE RESISTANT MIMICS OF BINDING RECEPTORS FOR NUCLEIC ACID-BINDING PROTEINS; 5-LIPOXYGENASE INHIBITORS; DIAGNOSIS; ANALYZING ISIS PHARMACEUTICALS, INC. (US) 1996-08-06 US disclosed